ACROBAT - a multi-stain breast cancer histological whole-slide-image data set from routine diagnostics for computational pathology
Data files
Data files
Documentation files
Documentation files
Citation and access
Citation and access
Data access level:
Creator/Principal investigator(s):
Research principal:
Data contains personal data:
No
Citation:
Language:
Method and outcome
Method and outcome
Unit of analysis:
Population:
Anonymised female primary breast cancer patients from the Stockholm region
Study design:
- Observational study
Description of sampling:
A subset of the whole-slide-images that were generated in terms of the CHIME study were randomly selected for the ACROBAT data set. Training and validation data are a random subset, whereas the test data was generated using stratified sampling, taking into account biomarker statuses and the scanner model that was used to generate the respective whole-slide-image.
Time period(s) investigated:
Number of individuals/objects:
1153
Data format/data structure:
Data collection
Data collection
Description of the mode of collection:
Archived routine clinical diagnostic tissue slides with tissue material were scanned using whole-slide-image scanners at Karolinska Institutet.
Time period(s) for data collection:
2012 - 2018
Data collector:
- Karolinska Institutet
Opens a new window at ror.org.
ROROpens in a new tab
Instrument
Instrument
Name:
NanoZoomer XR
Type:
Technical instrument(s)
Description of the instrument:
Hamamatsu whole-slide-imaging scanner.
Name:
NanoZoomer S360
Type:
Technical instrument(s)
Description of the instrument:
Hamamatsu whole-slide-imaging scanner
Geographic coverage
Geographic coverage
Geographic location:
Administrative information
Administrative information
Responsible department/unit:
Department of Medical Epidemiology and Biostatistics [C8]
Contributor(s):
- Sonja Koivukoski - University of Eastern Finland - Institute of Biomedicine
- Circe Carr - University of Turku - Institute of Biomedicine
- Sandra Pouplier - Zealand University Hospital - Department of Surgical Pathology
- Aino Kuusela - University of Turku - Institute of Biomedicine
Ethics Review:
Stockholm - 2017/2106-31
Amendment: 2018/1462-32
Funding
Funding
Funding agency:
- Swedish Research Council
Opens a new window at ror.org.
ROROpens in a new tab
Award number:
2019-00947_VR
Award title:
Advancing Breast Cancer histopathology towards AI-based Personalised medicine (ABCAP)
Funding information:
Manual histopathological assessment is the main mode to detect presence of breast cancer (BC), identify clinically relevant cancer, and to establish diagnosis. However, there is a shortage of pathology expertise and also a high inter-assessor. This leads to prolonged response times and unequal access to top-quality histopathology assessments for cancer patients. Misclassifications in histopathology assessments will cause both over- and under-treatment. We hypothesise that it is now possible to develop advanced image-based prediction models based on artificial intelligence (AI) and deep-learning (DL) techniques for BC histopathology assessment that match or outperform the performance of top-level human experts. In this research programme we will develop and validate state-of-the-art AI-based models for BC routine histopathology and for improved patient stratification in respect to prognosis and treatment response. Through both retrospective and prospective validation we will establish evidence towards clinical translation. Our studies are based on large-scale population samples, ensuring unbiased data and models. Novel methodologies for stain-free and multi-stain analysis will also be developed. The project aims to improve the quality of BC histopathology assessments by reducing errors and inter-assessor variability, enhancing patient stratification and reducing over- and under-treatment of patients, and contribute towards more efficient and reliable routine pathology.
Funding agency:
- ERA PerMed
Award number:
ERAPERMED2019-224-ABCAP
Award title:
Advancing Breast Cancer histopathology towards AI-based Personalised medicine
Funding agency:
- Swedish Cancer Society
Opens a new window at ror.org.
ROROpens in a new tab
